Southwest Airlines Co vs Twist Bioscience Corp — how do they compare? Southwest Airlines Co trades at $41.28 (market cap $20.23B), while Twist Bioscience Corp trades at $162.26 (market cap $10.08B). The key difference: Southwest Airlines Co is far larger — about 2× Twist Bioscience Corp's market cap, and Southwest Airlines Co pays a 1.74% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 65 Days and Twist Bioscience Corp for 27 Days on average.
| LUV | TWST | |
|---|---|---|
Market Cap | $20.23B | $10.08B |
Volume | 14,560,422 | 4,229,037 |
Sector | Industrials | Health |
52-Week High | $54.80 | $205.00 |
52-Week Low | $29.67 | $25.45 |
Typical Hold Time | 65 Days | 27 Days |
Enterprise Value | $23.33B | $10.01B |
Dividend Yield | 1.74% | — |
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $41.15, down 1.37% on the day, amid a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 25.85 and net income margin of 2.78%, while cash flow trends indicate a projected recovery in 2026. Recent news highlights the company's commercial transformation initiatives, including new fare structures and lounge plans, aiming to boost profitability.
Outlook remains cautiously optimistic with a consensus price target of $49.61, suggesting upside potential, though risks include volatile fuel costs and competitive pressures. The stock's valuation appears reasonable relative to sales, but investors should weigh near-term operational headwinds against long-term strategic gains.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →